) surged on Wednesday following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
The Florida outcome represents a “nice early Christmas present for the defendants. Was this all just a storm in a tea-cup after all?,” Bernstein analysts wrote in a note. Originally marketed by a forerunner of GSK, the medicine has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers.
In the first few of hours of Wednesday trading, more of GSK’s London-listed stock changed hands than the average for a full day over the past five years, according to Refinitiv data.) was up following the late Tuesday announcement that it has reached a deal with Elliott Management, the activist investment firm that has offered up ideas on how to improve operations at the image sharing and social media service company.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: KitcoNewsNOW - 🏆 13. / 78 اقرأ أكثر »
مصدر: fpinvesting - 🏆 43. / 63 اقرأ أكثر »
مصدر: globeandmail - 🏆 5. / 92 اقرأ أكثر »